Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp. develops and licenses DehydraTECH, a patented oral drug delivery formulation and processing platform designed to improve how active pharmaceutical ingredients enter the bloodstream. News about LEXX centers on GLP-1 drug delivery research, DehydraTECH-semaglutide compositions, preclinical and human study updates, intellectual property activity, and pharmaceutical partner evaluations under material transfer arrangements.
Company updates also cover Lexaria's investor communications, oral drug delivery market commentary, and applications of DehydraTECH across pharmaceuticals, nutraceuticals, over-the-counter products, and consumer formats. Recurring themes include bioabsorption, tolerability, blood-brain-barrier delivery, research laboratory activity, and the company's IP licensing business model.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has successfully closed its underwritten public offering, raising approximately $11.04 million by issuing 1,828,571 units, each consisting of one share of common stock and one warrant priced at $5.25 per unit. The warrants have an exercise price of $6.58 per share and are valid for five years. The offering was managed by H.C. Wainwright & Co., which also exercised its full option to purchase additional shares. The Company's stock began trading on Nasdaq under the symbols LEXX and LEXXW after a 1-for-30 reverse split.